Phase <scp>II</scp> study results of a replacement therapy for hereditary angioedema with subcutaneous C1‐inhibitor concentrate

Abstract

Subcutaneous volume-reduced CSL830 was well tolerated and led to a dose-dependent increase in physiologically relevant functional C1-INH plasma levels. A clinical outcome study of SC CSL830 in patients with HAE warrants further investigation.